Navigation Links
New MedPredict Report Assesses Current Outlook for Anticoagulants Market
Date:2/20/2009

Multi-Specialty Physician Panel Weighs in on Likely Positioning for Lilly/Daiichi's Prasugrel

SCOTTSDALE, Ariz., Feb. 20 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies developing anticoagulant therapies. This report is based on primary interviews conducted with cardiovascular experts from North America and Europe immediately following the American Society of Hematology (ASH) annual meeting.

"Anticoagulation therapy is being studied in a variety of settings, including elective and non-elective surgery, acute coronary syndrome, prevention and treatment of deep vein thrombosis/pulmonary embolism, secondary prevention of strokes in patients being treated for atrial fibrillation, and oncology," says Jeff Berk, MedPredict president. "Our Thought Leaders share their opinions on antithrombotics and antiplatelets driven by different patient populations and differing therapeutic goals."

The report addresses the following questions:

  • Which patient populations are most likely to be prescribed Effient (prasugrel), and how are physicians likely to balance efficacy versus bleeding risk? How does this vary by specialty?
  • Is daily oral anticoagulant therapy preferable to a monthly parenteral dose?
  • What do acute coronary syndrome treaters want that pharma is not currently providing?
  • How do different specialists view the strengths and weaknesses of the various anticoagulant therapies in development?

"Our panel reviews all of the key compounds in the pipeline and distills a massive amount of information down to the most critical insights drug developers should have for decision-making," according to Dr. Berk.

Companies mentioned in this report include: Astellas, AstraZeneca, Bayer-Schering, Bristol-Meyers Squibb, Daiichi Sankyo, GlaxoSmithKline, Lilly, Pfizer, Portola, Sanofi-Aventis, Schering-Plough, Takeda, The Medicines Company.

This report can be purchased by contacting MedPredict (www.medpredict.com).

About MedPredict

MedPredict maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cardiovascular Meds May Be Beneficial in Alzheimers Disease, According to MedPredict Report
2. MedPredict Publishes Two New Reports Providing Expert Analysis of Malignant Hematology Drug Development
3. Virginia Tech Report Has National Importance
4. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
5. GAO Report Confirms: Medicare Underpays for Anesthesia Services; Nurse Anesthetists Assure Seniors Access to Safe Anesthesia Care
6. Haemacure Reports Third Quarter 2007 Results
7. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
8. Biotech Finishes on a High in August, Burrill Report Says
9. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
10. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
11. MDS Reports Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy Specialists (TexPTS) is ... in Building 2. The clinic is the group’s second in New Braunfels and 22nd ... company’s second New Braunfels location brings things full circle for the group, “It’s crazy ...
(Date:3/23/2017)... ... ... The IoT (Internet of Things) is revolutionizing the way the world operates. ... individual consumers alike. Laboratories can maximize their profit margin by increasing throughput. ... to $11 trillion dollars by the year 2025. McKinsey expects the IoT to have ...
(Date:3/23/2017)... York, NY (PRWEB) , ... March 23, 2017 , ... 82% of adults are unaware ... 3 kids do not brush their teeth the minimum two times a day that dentists ... with students missing 51 million hours of school and adults missing 164 million hours of ...
(Date:3/23/2017)... ... March 23, 2017 , ... March is National Kidney Month – the perfect ... comes to maintaining good health. Every day, two kidneys filter about 120 to 150 ... of your blood, eliminating waste, regulating fluid levels and blood pressure, supporting bone health ...
(Date:3/23/2017)... ... March 23, 2017 , ... The StayWell Company announced ... The accreditation covers StayWell’s asthma, coronary artery disease, congestive heart failure, chronic obstructive ... that have excellent programs for the delivery and improvement of disease management and ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... Prima BioMed has presented encouraging early signs ... combination with Keytruda, with one of the six melanoma ... response. Recruitment in the second cohort is complete and ... by Q317. Preliminary efficacy data from the 15-patient, run-in ... mid-year (recruitment in the 226-patient Phase IIb component is ...
(Date:3/23/2017)... , March 23, 2017 ... consolidated vendor landscape with the top five players ... in 2015. These companies are Stryker Sustainability Solutions, ... Health Services, Inc., and VANGUARD AG. Despite the ... devices market is witnessing the prevalence of fierce ...
(Date:3/23/2017)... MUMBAI , March 23, 2017 ... de Piramal Enterprises Limited, anuncia el nombramiento de ... PPS ofrece una plataforma de servicios integrados completa ... Needleman desempeñará un cargo clave en el crecimiento ... comercial, Needleman será responsable de impulsar todas las ...
Breaking Medicine Technology: